DAVID GRANOVSKY

Posts Tagged ‘UK’

REUTERS UPDATE

In ALL ARTICLES on January 4, 2012 at 12:09 pm
UK wants results of breast implant review this week
LONDON (Reuters) – Britain expects the results of a review of breast implant safety to come this week following a global health scare focused on products from a now defunct French company, Health Secretary Andrew Lansley said on Wednesday. | Full Article
Want your kids to do better in school? Try exercise
January 04, 2012 08:17 AM ET
(Reuters) – Children who get more exercise also tend to do better in school, whether the exercise comes as recess, physical education classes or getting exercise on the way to school, according to an international study. | Full Article
Daycare providers say kids are too inactive
January 04, 2012 09:22 AM ET
NEW YORK (Reuters Health) – Potential playground hazards, a focus on classroom learning and boring play equipment have children spending too little time being physically active at daycare, according to a survey of staff members at child care centers in Ohio. | Full Article

BENNY HILL IS ALIVE AND WELL AS BRITAIN GOES BLIND

In ALL ARTICLES on September 23, 2011 at 7:00 am

Remember in the final scene of every episode of Benny Hill where he does something really scandalous and then gets chased by the entire cast around and around in circles?  Turns out, Benny Hill is ALIVE AND WELL and advising Britain on their medical protocols!  https://i2.wp.com/www.webtvwire.com/wp-content/uploads/2010/06/the-benny-hill-show-logo.jpg

You see, Britain, like the USA, is chasing this fleet footed “embryonic stem cell treatment comedy of errors” around and around in circles just like in the Benny Hill episodes.  Every week, the same scene is played out with Benny running, the entire cast chasing and he never gets caught.  So in Art, so in life.  Britain is chasing embryonic stem cells used for treatment of optic diseases.  And remember…

  • Embryonic stem cells STILL have ZERO successful clinical trials
  • Embryonic stem cells STILL cause cysts and tumors that can become cancerous (wait 20 years and ask again though)
  • Embryonic stem cells STILL have rejection issues that require immunosuppressive drugs
  • Embryonic stem cells STILL carry the genetic anomalies of the donor
ON THE OTHER HAND…

So on top of wasting time chasing a cure with no prior history of success and huge negative side effects, thy are running right past a treatment with a huge history of success and safety and trials.

So cue up the cameras, get everyone in costume and let’s start that famous music going as everyone chases embryonic stem cell treatments around and around.  Wait! STOP! Hold it! CUT!

How on earth can we explain the entire medical community and government running right past what already works?  Got it! Give them all blindfolds!  That way they can be assured to miss the forest but they will hit every damn tree in it and so will the patients, patiently waiting for treatments which will never come!

…annndddd   ACTION!!!

Iris of a human eye

First trial of embryonic stem cell treatment in Europe gets green light

Patients in Britain with an eye disease that leads to blindness will take part in Europe’s first human embryonic stem cell trial

British surgeons are to take part in the first trial in patients of a human embryonic stem cell therapy to gain approval from regulators in Europe.

Surgeons at Moorfields Eye Hospital in London will inject cells into the eyes of 12 patients with an incurable eye disease called Stargardt’s macular dystrophy, one of the main causes of blindness in young people…

Read more

ADULT STEM CELL voice box transplant trials could begin in 2013

In STEM CELLS IN THE NEWS on March 31, 2011 at 5:51 pm

Professor Birchall carried out the world’s first stem cell transplant of a windpipe in 2008.  Now he wants a clinical trial so he can help 1,300 patients a year with larynx problems. Well done sir!  – dg

Stem cell voice box transplant trials could begin in 2013

Speaking at the UK National Stem Cell Network annual science meeting today in York (30 March), Professor Martin Birchall will announce that the first clinical trials for stem cell voice transplants will begin in 2013, thanks to a million pounds provided by the Medical Research Council (MRC).

This revolutionary new kind of transplant treatment could change the lives of to 1300 patients a year in the UK who suffer serious problems with breathing, speaking and swallowing.

Loss of a working larynx (voice box) not only affects speech, swallowing, breathing, but also smell, taste, coughing, lifting and kissing, affecting thousands of people in the UK. Having carried out the world’s first stem cell transplant of a windpipe in 2008, Professor Birchall will be heading up a team to formally assess whether a similar approach can be used to repair problems in a voice box.

This research opens up new possibilities for patients receiving other kinds of transplants as well. One of the main problems currently facing those in need of donor organs is that they will need to take drugs for the rest of their lives as a result of the transplant. This new project, known as RegenVOX proposes that by using stem cells, this method could potentially help restore the patient’s own immune system and reduce the need for immuno-suppresant drugs.

Health News – Stem cell voice box transplant trials could begin in 2013.

UK to set up new clinical trials agency

In STEM CELLS IN THE NEWS on August 6, 2010 at 12:49 pm

We will keep our eyes on this development and see if the change creates an improved clinical trial environment. -dg

UK to set up new clinical trials agency 5 August 2010

https://i1.wp.com/www.2cuk.co.uk/img/uk%20flag.jpg

Policy | Life sciences | Clinical trials | United Kingdom

Nuala Moran

The UK government is to set up a single agency to supervise clinical trials, in a bid to cut through the bureaucracy that has led to a flight of academic clinical research from the country.

The formation of the new agency is proposed at the same time as the axe is taken to quangos and other arms-length agencies across all other areas of government. This includes plans to close 15 agencies that support the National Health Service (NHS), leaving only three existing agencies intact. The new clinical trials body will be in addition to these three.

Health bodies facing the chop include the Human Tissue Authority, which oversees the European Union Advanced Tissue Products legislation and the Human Fertilisation and Embryology Authority, which is responsible amongst other things for awarding licenses for human cloning for embryonic stem cell research.

The proposed clinical trials agency is presented as the route around the red tape that has engulfed clinical research since the coming into force in April 2004 of the EU Clinical Trials Directive. This was intended to harmonise clinical trials activity across Europe, but is widely acknowledged to have had the opposite effect, with different member states implementing its requirements more, or less, stringently.

UK participation in global clinical trials dropped from 6 per cent in 2002, to 2 per cent in 2006…

via Science|Business UK to set up new clinical trials agency.

New approach of screening drugs that encourage stem cells to repair damaged tissue

In STEM CELLS IN THE NEWS on July 19, 2010 at 2:42 pm

New approach of screening drugs that encourage stem cells to repair damaged tissue

12. July 2010 06:13

Professor Fiona Watt will today (12 July) give the Anne McLaren Memorial Lecture at the UK National Stem Cell Network annual science meeting and will detail a new approach to screening for drugs that target stem cells. To begin with, this is being developed for adult skin stem cells, giving hope for new drugs to promote wound healing and aid the use of stem cells to, for example, treat severe burns. This technique can also be applied to a wide range of stem cells, opening up the possibilities for harnessing stem cells in regenerative medicine.

Professor Watt said “We are very interested in developing regenerative medicine as a way to heal our bodies when they can’t heal themselves – when the damage from an injury or disease is too severe, for example. For this type of approach to be successful it is important to have powerful ways of identifying the processes that stimulate stem cells to renew themselves or mature into the cells that are needed for healing. When we know what these processes are, we can use that knowledge to develop new treatments…

via New approach of screening drugs that encourage stem cells to repair damaged tissue.

Natural Health Care: Stem cell therapy ‘first’ in trial on arthritic knees

In ALL ARTICLES on July 13, 2010 at 12:59 pm

This article is interesting because the UK has been typically focused on embryonic stem cell research.  They are now accepting the benefits of safety of adult stem cells and putting their research time and money into it.  Perhaps the US should follow suit so they are not the last kid on the block to get their “big wheel” or “x-box?” – dg

Tuesday, July 13, 2010

Stem cell therapy ‘first’ in trial on arthritic knees

BBC news A stem cell therapy for osteoarthritis is to be tested on patients in the UK for the first time.

A year-long trial, funded by Arthritis Research UK, will mix stem cells with cartilage cells in the lab and inject them back into damaged knee joints.

Bone marrow stem cell
Stem cell therapy is a less invasive treatment than joint replacement

The new treatment could be an alternative to joint replacement surgery, experts hope.  Scientists from Keele University will study up to 70 people from the end of this year.  The trial will be run at the Robert Jones and Agnes Hunt Orthopaedic Hospital in Oswestry, Shropshire as part of a five-year research programme.  Three treatments are being tested in a randomised trial of patients with osteoarthritis of the knee.

Cell therapy

Using keyhole surgery, a patient’s cartilage cells – also known as chondrocytes – and bone marrow stem cells will be removed and grown in a laboratory for three weeks.  We are using the body’s own cells to repair damaged joints. The hope is that it will be permanent and long-term.

Professor Sally Roberts, Keele University

They will then be re-implanted separately in some patients, and mixed together in other patients, into the area of damaged or worn cartilage.  Scientists will then test the effectiveness of all three types of cell therapy, based on the quality of the new cartilage formed over a period of 12 months.  Chondrocytes – cartilage cells – have been grown in a lab and re-injected into patients’ damaged knees for the last 15 years.  But scientists now want to find out if combining cartilage cells and stem cells in the same process could work better, and specifically if one type of cell stimulates the other.

Less invasive

Osteoarthritis affects an estimated 8m people in the UK.  The condition is caused by wear and tear to the surface of joints, leading to stiffness and pain.  At present there is little effective treatment for osteoarthritis patients, apart from pain-relieving drugs and joint replacement.  The trial will focus on knee joints, but the results could have implications for other joints, say the scientists.  The advantage of stem cell treatment is that it’s much less invasive than major joint replacement surgery.  Sally Roberts, professor of orthopaedic research at Keele University and lead scientist on the trial, says it’s also a more “biological approach”.

“We are using the body’s own cells to repair damaged joints.

The hope is that it will be permanent and long-term repair,” she said.

via Natural Health Care: Stem cell therapy ‘first’ in trial on arthritic knees.

Tuesday, July 13, 2010

Stem cell therapy ‘first’ in trial on arthritic knees

BBC news A stem cell therapy for osteoarthritis is to be tested on patients in the UK for the first time.A year-long trial, funded by Arthritis Research UK, will mix stem cells with cartilage cells in the lab and inject them back into damaged knee joints.

Bone marrow stem cell
Stem cell therapy is a less invasive treatment than joint replacement
The new treatment could be an alternative to joint replacement surgery, experts hope.

Scientists from Keele University will study up to 70 people from the end of this year.

The trial will be run at the Robert Jones and Agnes Hunt Orthopaedic Hospital in Oswestry, Shropshire as part of a five-year research programme.

Three treatments are being tested in a randomised trial of patients with osteoarthritis of the knee.

Cell therapyUsing keyhole surgery, a patient’s cartilage cells – also known as chondrocytes – and bone marrow stem cells will be removed and grown in a laboratory for three weeks.

We are using the body’s own cells to repair damaged joints. The hope is that it will be permanent and long-term

Professor Sally Roberts, Keele University

They will then be re-implanted separately in some patients, and mixed together in other patients, into the area of damaged or worn cartilage.

Scientists will then test the effectiveness of all three types of cell therapy, based on the quality of the new cartilage formed over a period of 12 months.

Chondrocytes – cartilage cells – have been grown in a lab and re-injected into patients’ damaged knees for the last 15 years.

But scientists now want to find out if combining cartilage cells and stem cells in the same process could work better, and specifically if one type of cell stimulates the other.

Less invasive

Osteoarthritis affects an estimated 8m people in the UK.

The condition is caused by wear and tear to the surface of joints, leading to stiffness and pain.

At present there is little effective treatment for osteoarthritis patients, apart from pain-relieving drugs and joint replacement.

The trial will focus on knee joints, but the results could have implications for other joints, say the scientists.

The advantage of stem cell treatment is that it’s much less invasive than major joint replacement surgery.

Sally Roberts, professor of orthopaedic research at Keele University and lead scientist on the trial, says it’s also a more “biological approach”.

“We are using the body’s own cells to repair damaged joints. The hope is that it will be permanent and long-term repair,” she said.

Master gene that can kill cancer

In STEM CELLS IN THE NEWS on September 14, 2009 at 6:15 pm

Key master gene that can KILL cancer identified by British scientists

By Fiona Macrae

Last updated at 7:49 AM on 14th September 2009

Colon cancer cells

Colon cancer cells: A ‘masterswitch’ in the body’s battle against cancer has been identified by British scientists

A ‘masterswitch’ in the body’s battle against cancer has been identified by British scientists, raising hope of new treatments.

The key gene triggers the production of blood cells capable of fighting – and killing – tumour cells.

The cells form part of the body’s natural armoury against disease and we all have some.

But making more could bolster our defence, saving some of the 155,000 lives lost each year to cancer in the UK.

via Found, master gene that can kill cancer | Mail Online.

UK study for people with MSTo members of The Patients Voice

In ALL ARTICLES on April 22, 2009 at 12:31 pm
UK study for people with MSTo members of The Patients Voice

Belle Shale
April 21 at 6:33am

The Patients Voice would like to let you know about a new survey opportunity in the UK

We would like to offer you £15.00 for taking part in a 15 minute online survey about Relapsing-Remitting Multiple Sclerosis.
To qualify you will have to meet the following criteria:
a) Have been diagnosed with Relapsing-Remitting Multiple Sclerosis
b) Have been diagnosed by a neurologist
c) Live in the UK
If you wish to take part please email me at Belinda.shale@healthcarelandscape.com

entitling your email RRMS or Relapsing-Remitting Multiple Sclerosis. I will arrange for one of my colleague to send you an invitation email as soon as possible.
Alternatively you can join us at The Patients Voice by clicking here
http://www.thepatientsvoice.org/Join_The_Patients_Voice.asp
This will mean that you will be eligible for many more projects in the future.
Please remember that this project is only open till Friday 8th May 2009 so reply today to ensure you place on the survey.
Thanks very much in advance for your interest.
Best wishes
Belinda

Stem Cell Innovation At Risk In UK, Studies Find

In ALL ARTICLES, BUSINESS OF STEM CELLS on April 6, 2009 at 12:42 pm

money-stacks

ScienceDaily (Apr. 6, 2009) — Despite great hopes for stem cell therapy, major structural and cultural changes within the National Health Service (NHS) are needed if it is to succeed in the UK. Currently the chances of getting effective treatments into routine use in the short-term are small and the industry is at serious risk of ‘market failure’.

These are the findings of two major studies into the commercialisation and adoption of stem cell therapy carried out by researchers at The University of Nottingham.

Dr Paul Martin, from the Institute of Science and Society said: “While the government has identified regenerative medicine as a national priority and the US has lifted its ban on stem cell therapy, urgent public policy action is needed if it is to become a reality. Although cell therapy is now established as an important branch of medicine, innovative firms struggle to make money, putting the UK industry in a very vulnerable position in the short term. Unless the situation changes the industry will contract and the progress needed to develop important cell therapies will be adversely affected.”

via Stem Cell Innovation At Risk In UK, Studies Find.

CATCH UP! – UK’s Stem Cell Sciences acquired by US company

In ALL ARTICLES, STEM CELLS IN THE NEWS on March 5, 2009 at 11:27 am

shhWith the ever so quiet announcement that the NIH is getting into adult stem cell research, the bugle has been (oh so quietly) blown for the United States.  It is no longer a question of whether the US is 5-10 years behind in adult stem cell research, it is only a question of what can be done?

StemCells, Inc is one of the first to see this and their purchase of the UK stem cell company may allow them to pursue stem cell R&D outside the US is an effort to keep pace with the rest of the world and try to CATCH UP! – dg

Thursday , March 05, 2009

US company StemCells Inc is to expand its capabilities in the field with the purchase of UK based Stem Cell Sciences for $4.8 million.

Established in 1994, Stem Cell Sciences is based in Cambridge in the UK and specialises in developing stem cells to be used in drug discovery and regenerative medicine research.

The company has a second research base in Monash near Melbourne, Australia, and this will also be included in the sale to the US group.

California-based StemCells Inc is developing stem cell products for therapeutic use in humans. It says its combination with Stem Cell Sciences will provide a major boost to its commercial base.

“The industrial logic of this acquisition is compelling,” said Martin McGlynn, president and chief executive of StemCells. “StemCells has established itself as a world leader in tissue-derived stem and progenitor cells for therapeutic uses, while Stem Cell Sciences has focused on non-therapeutic applications for embryonic and tissue derived stem cells, such as cell-based assays for drug discovery and screening.”

McGlynn said the combination of three distinct stem cell platforms, adult, embryonic and iPS cells, for both therapeutic and drug discovery applications would allow the company to diversify and pursue near-term opportunities while continuing to develop its therapeutic products.

via Pharmafocus.com.

%d bloggers like this: